See more : M&C Saatchi plc (SAA.L) Income Statement Analysis – Financial Results
Complete financial analysis of Olema Pharmaceuticals, Inc. (OLMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olema Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cetus Capital Acquisition Corp. (CETU) Income Statement Analysis – Financial Results
- CHC Resources Corporation (9930.TW) Income Statement Analysis – Financial Results
- Fiore Cannabis Ltd. (FIOR.CN) Income Statement Analysis – Financial Results
- AerSale Corporation (ASLEW) Income Statement Analysis – Financial Results
- DNXCorp SE (ALDNX.PA) Income Statement Analysis – Financial Results
Olema Pharmaceuticals, Inc. (OLMA)
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| Gross Profit | -377.00K | -1.66M | -1.66M | -11.00K | -9.03K | -8.24K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.14M | 82.27M | 51.10M | 13.70M | 3.92M | 1.69M |
| General & Administrative | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Other Expenses | 0.00 | -27.00K | -47.00K | 0.00 | 0.00 | -31.00K |
| Operating Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Cost & Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Interest Income | 8.32M | 2.23M | 442.00K | 60.00K | 7.00K | 4.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 653.00K | 0.00 | 28.00K |
| Depreciation & Amortization | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| EBITDA | -104.58M | -103.13M | -69.43M | -21.52M | -4.31M | -2.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.96M | -106.99M | -71.49M | -21.53M | -4.32M | -2.08M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.31M | 2.20M | 395.00K | -593.00K | 7.00K | -118.00K |
| Income Before Tax | -96.66M | -104.79M | -71.10M | -22.12M | -4.32M | -2.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.20M | -210.00K | 642.00K | -155.86K | -90.00K |
| Net Income | -96.66M | -102.59M | -70.89M | -22.76M | -4.32M | -2.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| EPS Diluted | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| Weighted Avg Shares Out | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
| Weighted Avg Shares Out (Dil) | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen,...
Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update
SAN FRANCISCO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today provided an update on recent...
Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference
SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen,...
Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the appointment of Yi...
Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
SAN FRANCISCO, March 17, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today reported financial results for the...
Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced a poster presentation on OP-1250, a...
Analyst talks Biotech sector, offers three picks for 2021
The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable in 2021. ‘Exciting stories' for 2021 While looking at...
Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced two posters relating to OP-1250, a...
Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the closing of its previously announced...
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week
In a scramble to go public ahead of the holiday, six IPOs and 15 SPACs went public this past week led by breast cancer biotech Olema Pharmaceuticals, which soared 158% on its first day. New filings continued to pour in,...
Source: https://incomestatements.info
Category: Stock Reports